Tzaridis, Theophilos and Weller, Johannes and Bachurski, Daniel and Shakeri, Farhad and Schaub, Christina and Hau, Peter and Buness, Andreas and Schlegel, Uwe and Steinbach, Joachim-Peter and Seidel, Clemens and Goldbrunner, Roland and Schaefer, Niklas and Wechsler-Reya, Robert J. and Hallek, Michael and Scheffler, Bjoern and Glas, Martin and Haeberle, Lothar and Herrlinger, Ulrich and Coch, Christoph and Reiners, Katrin S. and Hartmann, Gunther (2023) A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. INTERNATIONAL JOURNAL OF CANCER, 152 (2). pp. 308-319. ISSN 0020-7136, 1097-0215
Full text not available from this repository. (Request a copy)Abstract
Detection of tumor progression in patients with glioblastoma remains a major challenge. Extracellular vesicles (EVs) are potential biomarkers and can be detected in the blood of patients with glioblastoma. In our study, we evaluated the potential of serum-derived EVs from glioblastoma patients to serve as biomarker for tumor progression. EVs from serum of glioblastoma patients and healthy volunteers were separated by size exclusion chromatography and ultracentrifugation. EV markers were defined by using a proximity-extension assay and bead-based flow cytometry. Tumor progression was defined according to modified RANO criteria. EVs from the serum of glioblastoma patients (n = 67) showed an upregulation of CD29, CD44, CD81, CD146, C1QA and histone H3 as compared to serum EVs from healthy volunteers (P value range: <.0001 to .08). For two independent cohorts of glioblastoma patients, we noted upregulation of C1QA, CD44 and histone H3 upon tumor progression, but not in patients with stable disease. In a multivariable logistic regression analysis, a combination of CD29, CD44, CD81, C1QA and histone H3 correlated with RANO-defined tumor progression with an AUC of 0.76. Measurement of CD29, CD44, CD81, C1QA and histone H3 in serum-derived EVs of glioblastoma patients, along with standard MRI assessment, has the potential to improve detection of true tumor progression and thus could be a useful biomarker for clinical decision making.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NEWLY-DIAGNOSED GLIOBLASTOMA; TEMOZOLOMIDE; EXOSOMES; CONCOMITANT; biomarkers; extracellular vesicles; glioblastoma; protein-signature; tumor-progression |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Mar 2024 11:08 |
| Last Modified: | 05 Mar 2024 11:08 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58358 |
Actions (login required)
 |
View Item |
